N2OFF to Become Nexentis with New Trading Symbol, Biotech Focus
N2OFF will change its name to Nexentis Technologies and ticker to NXTS on Nasdaq on Feb. 26, 2026, reflecting its transformation into an AI-driven computational biotech platform. The company completed acquisition of MitoCareX, integrating its MITOLINE™ discovery engine to develop mitochondrial-targeted oncology and anti-inflammatory drug candidates.
1. Rebranding and Symbol Change
On February 26, 2026, N2OFF Inc. will officially adopt the name Nexentis Technologies and transition its Nasdaq listing to the new trading symbol “NXTS.” This change is designed to signal the company’s strategic shift from cleantech investments into an AI‐driven computational biotech model focused on mitochondrial biology.
2. MitoCareX Acquisition and MITOLINE™ Platform
N2OFF completed the acquisition of MitoCareX Bio Ltd. on October 20, 2025, making it a wholly-owned subsidiary and integrating its proprietary MITOLINE™ discovery engine. The platform has already produced in vitro anti-tumor activity and preliminary anti-inflammatory results, validating its structure-guided virtual screening workflows against the mitochondrial SLC25 carrier family.
3. Pipeline Focus and Asset Management
Under the Nexentis brand, the company plans to advance a diversified pipeline of first-in-class small-molecule candidates against resistant cancers and inflammatory metabolic diseases, with preclinical candidate nominations underway. Concurrently, it will retain its RTB solar energy investments as a non-core asset base to optimize value while prioritizing drug discovery and development.